I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Sep 2020 - 25 Sep 2020

Human Studies, Pharmacology/Drug Development


2020 Oct

Lancet Neurol



Editor's Pick

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.


Mulleners WM, Kim B-K, Láinez M J, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC
Lancet Neurol. 2020 Oct; 19(10):814-825.
PMID: 32949542.


Many patients who require migraine preventive treatment have not been able to tolerate or have not responded to multiple previous preventive medications. We aimed to assess the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide, in patients with migraine who had not benefited from preventive medications from two to four categories.